Viridian Therapeutics to Webcast Veligrotug Section 3 THRIVE-2 Topline Outcomes on December 16, 2024 By Investing.com
- The THRIVE-2 world part 3 medical trial evaluated the efficacy and…
Vera Therapeutics CEO Sells Inventory Value Over $821,000 By Investing.com
BRISBANE, Calif.—Fordyce Marshall, president and CEO of Vera Therapeutics Inc. (NASDAQ: VERA),…
Adagio Therapeutics Inventory Hits 52-Week Low of $0.57 Amid Challenges By Investing.com
Therapeutic Adagio Inc. (NASDAQ:) inventory fell to its 52-week low, touching a…
Kirby McInerney LLP Publicizes Investigation into Shareholder Claims Towards Utilized Therapeutics, Inc. (APLT) By Investing.com
New York, New York--(Newsfile Corp. - December 12, 2024) - Regulation agency…
An2 Therapeutics Director Robin Readnour Buys $86,708 in Inventory By Investing.com
Robin Shane Readnour, Director of AN2 Therapeutics, Inc. (NASDAQ:ANTX), not too long…
Scorpion Therapeutics Gives Scientific Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 By Investing.com
“Entered into collaboration with Pfizer to judge the triple mixture of STX-478…
Why Summit Therapeutics Inventory Soared 6% Friday
Therapeutic Summit (NASDAQ:SMMT) The inventory obtained an actual increase Friday with the…
Beam Therapeutics Announces New Data from the BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
All seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction >…
ADC Therapeutics Sees $52,478 Stock Sale By Redmile Group By Investing.com
The filing highlights the continued involvement of Redmile Group and its subsidiaries…
